Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Leukemia, Myeloid, Acute 2Testicular Neoplasms 1Testicular Germ Cell Tumor 1Small Cell Lung Carcinoma 1Rectal Diseases 1Pancreatic Neoplasms 1Neoplasms, Germ Cell and Embryonal 1Neoplasms by Site 1Neoplasms 1Melanoma 1Lung Neoplasms 1Intestinal Neoplasms 1Intestinal Diseases 1Gastrointestinal Neoplasms 1Gastrointestinal Diseases 1Gallbladder Neoplasms 1Digestive System Neoplasms 1Digestive System Diseases 1Colorectal Neoplasms 1Colonic Diseases 1Cholangiocarcinoma 1Carcinoma, Non-Small-Cell Lung 1Carcinoma, Hepatocellular 1

Interventions

Cisplatin 21Etoposide 20Carboplatin 20Topotecan 13pembrolizumab 12durvalumab 11Paclitaxel 10Irinotecan 9Nivolumab 7Gemcitabine 7tremelimumab 6atezolizumab 6Radiotherapy 6Docetaxel 6Pemetrexed 5Ipilimumab 5Cyclophosphamide 5rovalpituzumab tesirine 4budigalimab 4Specimen Handling 4Injections 4Doxorubicin 4Bortezomib 4130-nm albumin-bound paclitaxel 4venetoclax 3talazoparib 3olaparib 3fludarabine 3etoposide phosphate 3Platinum 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × Small Cell Lung Carcinoma × guadecitabine × Clear all
NCT03085849 2018-12-10

SGI-110 Plus Durvalumab/Tremelimumab in SCLC

Columbia University

Phase 1 Completed
2 enrolled
Thoracic

Small Cell Lung Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡